top of page

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...
JMG Logo transparent.png
Executive Spotlights

AbbVie Enters Obesity Drug Race with $2.25B Licensing Deal for Gubra’s Amylin Analog

  • Mar 12, 2025
  • 1 min read

Chicago, IL, March 3, 2025 (finance yahoo) -- AbbVie has partnered with Gubra in a deal worth up to $2.25 billion to develop an amylin analog for obesity treatment. The agreement includes a $350 million upfront payment and milestone-based incentives. This move positions AbbVie as a strong contender in the competitive weight-loss drug market.


Read full article here.

 
 
 

Recent Posts

See All
LIXTE Names Sidney Braun CEO of Liora Technologies

Boca Raton, FL, February 18, 2026 (Globe Newswire) -- LIXTE Biotechnology Holdings, Inc., a clinical-stage oncology company developing small-molecule cancer therapies and radiotherapy technologies,

 
 
 

Comments


Life Science Headlines
bottom of page